Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition and method for inhibiting inflammation

A technology of pharmaceutical composition and reductase inhibitor, which is applied in the field of pharmaceutical composition for inhibiting inflammation, and can solve problems such as difficult production process, inability to achieve improved effect, and increased manufacturing cost of hyaluronic acid preparations

Inactive Publication Date: 2012-05-23
CHINA MEDICAL UNIVERSITY(TW)
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, according to the teaching of this document, the mixture formed by simply mixing hyaluronic acid and aminomethylfolate cannot achieve the improvement effect, which makes the synthesis of the conjugate a necessary means
However, the preparation of the conjugate must use polypeptide raw materials and involve complicated synthetic steps, which will inevitably increase the manufacturing cost of hyaluronic acid preparations, not only cause difficulties in mass production processes, but also increase the economic burden of users, so it is widely used in clinical applications. limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and method for inhibiting inflammation
  • Pharmaceutical composition and method for inhibiting inflammation
  • Pharmaceutical composition and method for inhibiting inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] The cell test of embodiment 1 hyaluronic acid joint injection

[0043] Experiment A, cell culture

[0044] Fibroblast-like synoviocytes (FLS) from seven patients with rheumatoid arthritis were collected and cultured. First, the patient's joint synovium (synovium) was cut into small pieces, and then suspended in a DMEM (Dulbecco modified eagle's medium) medium (containing 1.5 g / L sodium bicarbonate (S6297, Sigma-Aldrich, St Louis , Missouri, U.S.), 1% penicillin-streptomycin-neomycin (P4083, Sigma-Aldrich), and 10% fetal bovine serum (04-001-1A, Biological Industries, Grand Island, New York, U.S.) and cultured for 3 days at 37°C in an atmosphere of 5% carbon dioxide.

[0045] Non-attached cells were washed away with phosphate buffered saline (PBS), the medium was changed, and the remaining attached cells were cultured for 2 weeks. The above procedure was repeated 3 to 6 times, and the remaining cells were fibroblast-like synoviocytes, which were used for the following...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

A pharmaceutical composition for inhibiting inflammation, comprising (a) hyaluronic acid, (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and (c) a pharmaceutically acceptable carrier, is provided. Also provided is a method for inhibiting inflammation in a mammal, comprising administrating to the mammal an effective amount of a composition comprising (a) hyaluronic acid and (b) an HMG-CoA reductase inhibitor.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for inhibiting inflammation, in particular to a pharmaceutical composition for arthritis. Background technique [0002] Arthritis is a common chronic disease, which is caused by joint pain caused by the degeneration of articular cartilage or inflammation of connective tissue, which in turn affects the normal movement of joints. According to the location and cause of occurrence, arthritis can be divided into more than 100 types, the most common ones include osteoarthritis (degenerative arthritis), rheumatoid arthritis, gouty arthritis, bacterial arthritis, stiffness spondyloarthritis, and lupus erythematosus. [0003] For the treatment of arthritis, conservative and non-surgical treatment is generally adopted at the initial stage. When the initial treatment fails, surgical treatment will be adopted. Initial treatment includes drug therapy and injection therapy. In drug therapy, steroid and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/728A61P29/00A61P19/02A61P19/06
CPCA61K31/366A61K31/728A61K45/06A61P19/00A61P19/02A61P19/06A61P29/00A61P43/00A61K2300/00
Inventor 林峯辉黄镫乐许弘昌
Owner CHINA MEDICAL UNIVERSITY(TW)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com